Atherosclerosis is a diffuse, systemic disorder of the large and medium-sized arterial vessels, affecting the coronary, cerebral and peripheral circulation. Chronic inflammatory processes are the central pathophysiological mechanism largely driven by lipid accumulation, and provide the substrate for occlusive thrombus formation. The clinical sequelae of acute arterial thrombosis, heart attack and stroke, are the most common causes of morbidity and mortality in the industrialized world. Such acute events are characterized by rupture or erosion of the atherosclerotic plaque leading to acute thrombosis. The atherosclerotic process and associated thrombotic complications are collectively termed atherothrombosis. The platelet is a pivotal mediator of various endothelial, immune, thrombotic and inflammatory responses and therefore a key player in the initiation and progression of atherothrombosis. A robust evidence base supports the clear clinical benefits of antiplatelet agents in the primary and secondary therapy of atherothrombotic disorders. Percutaneous coronary and peripheral interventions have an established central role in the management of atherothrombotic disease and demand a greater understanding of platelet biology. In this article, we provide a clinically orientated overview of the pathophysiology of arterial thrombosis and the evidence supporting the use of the various established antiplatelet therapies, and discuss new and future agents.
Aijan, R., Storey, R.F. and Grant, P.J. ( 2008) Aspirin resistance and diabetes mellitus. Diabetologia51: 385-390.
2.
Aktas, B., Utz, A., Hoenig-Liedl, P., Walter, U. and Geiger, J. ( 2003) Dipyridamole enhances NO/cGMPmediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies. Stroke34: 764-769.
3.
Aleil, B., Meyer, N., Cazenave, J.P., Mossard, J.M. and Gachet, C. ( 2005) High stability of blood samples for flow cytometric analysis of VASP phosphorylation to measure the clopidogrel responsiveness in patients with coronary artery disease. Thromb Haemost94: 886-887.
4.
Andersohn, F., Suissa, S. and Garbe, E. ( 2006) Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction . Circulation113: 1950-1957.
5.
Angiolillo, D.J., Fernandez-Ortiz, A., Bernardo, E., Alfonso, F., Macaya, C., Bass, T.A. et al. (2007) Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol49: 1505-1516.
6.
Antiplatelet Trialists’ Collaboration ( 1994) Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ308: 81-106.
7.
Antithrombotic Trialists’ Collaboration ( 2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ324: 71-86.
8.
Antithrombotic Trialists’ Collaboration, Baigent, C., Blackwell, L., Collins, R., Emberson, J., Godwin, J., Peto, R. et al. (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet373: 1849-1860.
9.
Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators (2001) Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction. Lancet358: 605-613.
10.
Baigent, C., Collins, R., Appleby, P., Parish, S., Sleight, P. and Peto, R. ( 1998) ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ316: 1337-1343.
11.
Barragan, P., Bouvier, J.L., Roquebert, P.O., Macaluso, G., Commeau, P., Comet, B. et al. (2003) Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv59: 295-302.
12.
Barsky, A.A. and Arora, R.R. ( 2006) Clopidogrel resistance: myth or reality? J Cardiovasc Pharmacol Ther11: 47-53.
13.
Bavry, A.A., Kumbhani, D.J., Helton, T.J., Borek, P.P., Mood, G.R. and Bhatt, D.L. ( 2006) Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med119: 1056-1061.
14.
Becker, R.C., Moliterno, D.J., Jennings, L.K., Pieper, P.S., Pei, J., Ziada, K.M. et al. (2009) Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet373: 919-928.
15.
Berger, J.S., Roncaglioni, M.C., Avanzini, F., Pangrazzi, I., Tognoni, G. and Brown, D.L. ( 2006) Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials . JAMA295: 306-313.
16.
Bhatt, D.L. ( 2004) Aspirin resistance: more than just a laboratory curiosity . J Am Coll Cardiol43: 1127-1129.
17.
Bhatt, D.L., Flather, M.D., Hacke, W., Berger, P.B., Black, H.R., Boden, W.E. et al. (2007) Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol49: 1982-1988.
18.
Bhatt, D.L., Fox, K.A., Hacke, W., Berger, P.B., Black, H.R., Boden, W.E. et al. (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med354: 1706-1717.
19.
Bhatt, D.L., Lincoff, A.M., Gibson, C.M., Stone, G.W., McNulty, S., Montalescot, G. et al. The CHAMPION PLATFORM Investigators (2009) Intravenous platelet blockade with cangrelor during PCI. N Engl J Med361: 2330-2341.
20.
Bonello, L., Camoin-Jau, L., Armero, S., Com, O., Arques, S., Burignat-Bonello, C. et al. (2009) Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol103: 5-10.
21.
Borna, C., Lazarowski, E., van Heusden, C., Ohlin, H. and Erlinge, D.(2005) Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thromb J3: 10.
22.
Buonamici, P., Marcucci, R., Migliorini, A., Gensini, G.F., Santini, A., Paniccia, R. et al. (2007) Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol49: 2312-2317.
23.
Cairns, J.A., Gent, M., Singer, J., Finnie, K.J., Froggatt, G.M., Holder, D.A. et al. (1985) Aspirin,
24.
sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med313: 1369-1375.
25.
Cannon, C.P., Husted, S., Harrington, R.A., Scirica, B.M., Emanuelsson, H., Peters, G. et al. (2007) Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in
26.
patients with non-st-segment elevation acute coronary syndrome: primary results of the Disperse-2 Trial. J Am Coll Cardiol50: 1844-1851.
27.
CAPRIE Steering Committee. (1996) A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet348: 1329-1339.
28.
Catella-Lawson, F., Reilly, M.P., Kapoor, S.C., Cucchiara, A.J., DeMarco, S., Tournier, B. et al. (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med345: 1809-1817.
29.
Catella, F., Healy, D., Lawson, J.A. and FitzGerald, G.A. ( 1986) 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci U S A83: 5861-5865.
30.
Chen, Z.M., Jiang, L.X., Chen, Y.P., Xie, J.X., Pan, H.C., Peto, R. et al. (2005) Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction randomised placebo-controlled trial . Lancet366: 1607-1621.
31.
Chen, W.H., Lee, P.Y., Ng, W., Tse, H.F. and Lau, C.P. ( 2004) Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol43: 1122-1126.
32.
Chew, D.P., Bhatt, D.L., Sapp, S. and Topol, E.J. ( 2001) Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation103: 201-206.
33.
Christiaens, L., Macchi, L., Herpin, D., Coisne, D., Duplantier, C., Allal, J. et al. (2002) Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease . Thromb Res108: 115-119.
34.
Cipollone, F., Ciabattoni, G., Patrignani, P., Pasquale, M., Di Gregorio, D., Bucciarelli, T. et al. (2000) Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation102: 1007-1013.
35.
Clemetson, K.J. ( 1995) Platelet activation: signal transduction via membrane receptors. Thromb Haemost74: 111-116.
36.
Collet, J.P., Hulot, J.S., Pena, A., Villard, E., Esteve, J.B., Silvain, J. et al. (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet373: 309-317.
37.
Cuisset, T., Frere, C., Quilici, J., Barbou, F., Morange, P.E., Hovasse, T. et al. (2006a) High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost4: 542-549.
38.
Cuisset, T., Frere, C., Quilici, J., Morange, P.E., Nait-Saidi, L., Carvajal, J. et al. (2006b) Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol48: 1339-1345.
39.
Curtis, J.P. and Krumholz, H.M. ( 2004) The case for an adverse interaction between aspirin and non-steroidal anti-inflammatory drugs: is it time to believe the hype? J Am Coll Cardiol43: 991-993.
40.
Davi, G., Ciabattoni, G., Consoli, A., Mezzetti, A., Falco, A., Santarone, S. et al. (1999) In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation99: 224-229.
41.
Davi, G., Guagnano, M.T., Ciabattoni, G., Basili, S., Falco, A., Marinopiccoli, M. et al. (2002) Platelet activation in obese women: role of inflammation and oxidant stress. JAMA288: 2008-2014.
42.
Davi, G. and Patrono, C. ( 2007) Platelet activation and atherothrombosis. N Engl J Med357: 2482-2494.
43.
De Luca, G., Suryapranata, H., Stone, G.W., Antoniucci, D., Tcheng, J.E., Neumann, F.J. et al. (2005) Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA293: 1759-1765.
44.
Douglas Jr, J.S., Holmes Jr, D.R., Kereiakes, D.J., Grines, C.L., Block, E., Ghazzal, Z.M. et al. (2005) Coronary stent restenosis in patients treated with cilostazol. Circulation112: 2826-2832.
45.
Eikelboom, J.W., Hirsh, J., Weitz, J.I., Johnston, M., Yi, Q. and Yusuf, S. ( 2002) Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation105: 1650-1655.
46.
Eisenstein, E.L., Anstrom, K.J., Kong, D.F., Shaw, L.K., Tuttle, R.H., Mark, D.B. et al. (2007) Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA297: 159-168.
47.
Ellis, S.G., Colombo, A., Grube, E., Popma, J., Koglin, J., Dawkins, K.D. et al. (2007) Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years. J Am Coll Cardiol49: 1043-1051.
48.
Ellis, S.G., Tendera, M., De Belder, M.A., Van Boven, A.J., Widimsky, P., Janssens, L. et al. (2008) Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med358: 2205-2217.
49.
Evans, D.J., Jackman, L.E., Chamberlain, J., Crosdale, D.J., Judge, H.M., Jetha, K. et al. (2009) Platelet P2Y(12) receptor influences the vessel wall response to arterial injury and thrombosis. Circulation119: 116-122.
50.
Falk, E., Shah, P.K. and Fuster, V. ( 1995) Coronary plaque disruption. Circulation92: 657-671.
51.
Fowkes, G. ( 2009) AAA: randomised controlled trial of low dose aspirin in the prevention of cardiovascular events and death in subjects with asymptomatic atherosclerosis. Presented ESC Barcelona, September 2009.
52.
Friend, M., Vucenik, I. and Miller, M. ( 2003) Research pointers: Platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ326: 82-83.
53.
Fuster, V. ( 1994) Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation90: 2126-2146.
54.
Garcia Rodriguez, L.A., Varas-Lorenzo, C., Maguire, A. and Gonzalez-Perez, A. ( 2004) Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation109: 3000-3006.
55.
Gawaz, M., Langer, H. and May, A.E. ( 2005) Platelets in inflammation and atherogenesis. J Clin Invest115: 3378-3384.
56.
Gilard, M., Arnaud, B., Cornily, J.C., Le Gal, G., Lacut, K., Le Calvez, G. et al. (2008) Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol51: 256-260.
57.
Greenbaum, A.B., Grines, C.L., Bittl, J.A., Becker, R.C., Kereiakes, D.J., Gilchrist, I.C. et al. (2006) Initial experience with an intravenous P2y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J151: 689, e681-689, e610.
58.
Greenbaum, A.B., Ohman, E.M., Gibson, C.M., Borzak, S., Stebbins, A.L., Lu, M. et al. (2007) Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the safety, tolerability and effect on patency in acute myocardial infarction (STEP-AMI) angiographic trial. Am Heart J154: 702-709.
59.
Grove, E.L., Hvas, A.M. and Kristensen, S.D.(2009) Immature platelets in patients with acute coronary syndromes. Thromb Haemost101: 151-156.
60.
Grotemeyer, K.H., Scharafinski, H.W. and Husstedt, I.W. ( 1993) Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res71: 397-403.
61.
Gum, P.A., Kottke-Marchant, K., Welsh, P.A., White, J. and Topol, E.J. ( 2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol41: 961-965.
62.
Gurbel, P.A. and Bliden, K.P. ( 2003) Durability of platelet inhibition by clopidogrel. Am J Cardiol91: 1123-1125.
63.
Gurbel, P.A., Bliden, K.P., Butler, K., Tantry, U.S., Gescheff, T., Wei, C. et al. (2009) Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable cornonary disease: the ONSET/OFFSET Study. Circulation120: 2577-2585.
64.
Gurbel, P.A., Bliden, K.P., Guyer, K., Cho, P.W., Zaman, K.A., Kreutz, R.P. et al. (2005a) Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol46(10): 1820-1826.
65.
Gurbel, P.A., Bliden, K.P., Samara, W., Yoho, J.A., Hayes, K., Fissha, M.Z. et al. (2005b) Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol46: 1827-1832.
66.
Gurbel, P.A., Bliden, K.P. and Tantry, U.S. ( 2006) Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the clear platelets 1b ctudy. J Am Coll Cardiol48: 2186-2191.
67.
Gurbel, P.A., Bliden, K.P., Zaman, K.A., Yoho, J.A., Hayes, K.M. and Tantry, U.S. ( 2005c) Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets: Results of the Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets (Clear Platelets) Study. Circulation111: 1153-1159.
68.
Halkes, P.H., van Gijn, J., Kappelle, L.J., Koudstaal, P.J. and Algra, A. ( 2006) Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet367: 1665-1673.
Hansson, J., Zanchetti, A., Carruthers, S.G., Dahlof, B., Elmfeldt, D., Julius, S. et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Trial (HOT) randomised trial. HOT study group. Lancet351: 1755-1762.
71.
Harrington, R.A., Stone, G.W., McNulty, S., White, H.D., Lincoff, A.M., Gibson, C.M. et al. (2009) Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med, [Epub ahead of print].
72.
Hedegaard, S.S., Hvas, A.M., Grove, E.L., Refsgaard, J., Rocca, B., Davi, G. et al. (2009) Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration. Thromb Res124: 96-100.
73.
Heemskerk, J.W., Bevers, E.M. and Lindhout, T. ( 2002) Platelet activation and blood coagulation. Thromb Haemost88: 186-193.
74.
Hermann, A., Rauch, B.H., Braun, M., Schror, K. and Weber, A.A. ( 2001) Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets12: 74-82.
75.
Ho, P.M., Maddox, T.M., Wang, L., Fihn, S.D., Jesse, R.L., Peterson, E.D. et al. (2009) Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome . JAMA301: 937-944.
76.
Hochholzer, W., Trenk, D., Bestehorn, H.P., Fischer, B., Valina, C.M., Ferenc, M. et al. (2006) Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol48: 1742-1750.
77.
James, S., Akerblom, A., Cannon, C.P., Emanuelsson, H., Husted, S., Katus, H. et al. (2009) Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the platelet inhibition and patient outcomes (Plato) trial. Am Heart J157: 599-605.
78.
Jefferson, B.K., Foster, J.H., McCarthy, J.J., Ginsburg, G., Parker, A., Kottke-Marchant, K. et al. (2005) Aspirin resistance and a single gene. Am J Cardiol95: 805-808.
79.
Kahn, M.L., Nakanishi-Matsui, M., Shapiro, M.J., Ishihara, H. and Coughlin, S.R. ( 1999) Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest103: 879-887.
80.
Kastrati, A., Mehilli, J., Neumann, F.J., Dotzer, F., ten Berg, J., Bollwein, H. et al. (2006) Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA295: 1531-1538.
81.
Kimmel, S.E., Berlin, J.A., Reilly, M., Jaskowiak, J., Kishel, L., Chittams, J. et al. (2004) The effects of nonselective non-aspirin non-steroidal antiinflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol43: 985-990.
82.
Klimt, C.R., Knatterud, G.L., Stamler, J. and Meier, P. ( 1986) Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol7: 251-269.
83.
Krasopoulos, G., Brister, S.J., Beattie, W.S. and Buchanan, M.R. ( 2008) Aspirin ‘‘resistance’’ and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ336: 195-198.
84.
Kuliczkowski, W., Witkowski, A., Polonski, L., Watala, C., Filipiak, K., Budaj, A. et al. (2009) Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J30: 426-435.
85.
Kulkarni, S., Dopheide, S.M., Yap, C.L., Ravanat, C., Freund, M., Mangin, P. et al. (2000) A revised model of platelet aggregation. J Clin Invest105: 783-791.
86.
Kuwahara, M., Sugimoto, M., Tsuji, S., Matsui, H., Mizuno, T., Miyata, S. et al. (2002) Platelet shape changes and adhesion under high shear flow. Arterioscler Thromb Vasc Biol22: 329-334.
87.
Labarthe, B., Theroux, P., Angioi, M. and Ghitescu, M. ( 2005) Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug . J Am Coll Cardiol46: 638-645.
88.
Lasser, G., Guchhait, P., Ellsworth, J.L., Sheppard, P., Lewis, K., Bishop, P. et al. (2006) C1qTNF-related protein-1 (CTRP-1): a vascular wall protein that inhibits collagen-induced platelet aggregation by blocking VWF binding to collagen. Blood107: 423-430.
89.
Lau, W.C., Waskell, L.A., Watkins, P.B., Neer, C.J., Horowitz, K., Hopp, A.S. et al. (2003) Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation107: 32-37.
90.
Loew, D. and Vinazzer, H. ( 1976) Dose-dependent influence of acetylsalicyclic acid on platelet functions and plasmatic coagulation factors. Haemostasis5: 239-249.
91.
Mason, P.J., Jacobs, A.K. and Freedman, J.E. ( 2005) Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol46: 986-993.
92.
Matetzky, S., Shenkman, B., Guetta, V., Shechter, M., Bienart, R., Goldenberg, I. et al. (2004) Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation109: 3171-3175.
93.
Mega, J.L., Close, S.L., Wiviott, S.D., Shen, L., Hockett, R.D., Brandt, J.T. et al. (2009) Cytochrome P-450 polymorphisms and response to clopidogrel . N Engl J Med360: 354-362.
94.
Mehilli, J., Kastrati, A., Schuhlen, H., Dibra, A., Dotzer, F., Von Beckerath, N. et al. (2004) Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation110: 3627-3635.
95.
Mehta, S.R., Bassand, J.P., Chrolavicius, S., Diaz, R., Fox, K.A., Granger, C.B. et al. (2008) Design and rationale of CURRENT-OASIS 7: a randomized, 2 X 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J156: 1080-1088e1.
96.
Mehta, S.R.Bassand, J.P., Chrolavicius, S., Diaz, R., Fox, K.A., Granger, C.B. et al. (2009) A 2x2 factorial randomized trial of optimal clopidogrel and aspirin dosing in patients with non-ST elevation acute coronary syndromes undergoing an early invasive strategy with an intent for PCI: the CURRENT-OASIS-7 trial. Presented ESC Barcelona , September 2009.
97.
Mehta, S.R., Yusuf, S., Peters, R.J., Bertrand, M.E., Lewis, B.S., Natarajan, M.K. et al. (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet358: 527-533.
98.
Michelson, A.D. ( 1996) Flow cytometry: a clinical test of platelet function. Blood87: 4925-4936.
99.
Michelson, A.D. ( 2004) Platelet function testing in cardiovascular diseases. Circulation110: e489-e493.
100.
Montalescot, G., Barragan, P., Wittenberg, O., Ecollan, P., Elhadad, S., Villain, P. et al. (2001) Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med344: 1895-1903.
101.
Montalescot, G., Sideris, G., Meuleman, C., Bal-dit-Sollier, C., Lellouche, N., Steg, P.G. et al. (2006) A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol48: 931-938.
102.
Moreno, R., Fernandez, C., Hernandez, R., Alfonso, F., Angiolillo, D.J., Sabate, M. et al. (2005) Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol45: 954-959.
103.
Moroz, L.A. ( 1977) Increased blood fibrinolytic activity after aspirin ingestion . N Engl J Med296: 525-529.
104.
Morrow, J.D., Frei, B., Longmire, A.W., Gaziano, J.M., Lynch, S.M., Shyr, Y. et al. (1995) Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med332: 1198-1203.
105.
Muller, I., Besta, F., Schulz, C., Massberg, S., Schonig, A. and Gawaz, M. ( 2003) Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement . Thromb Haemost89: 783-787.
106.
Muller, I., Seyfarth, M., Rudiger, S., Wolf, B., Pogatsa-Murray, G., Schomig, A. et al. (2001) Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart85: 92-93.
107.
Needs, C.J. and Brooks, P.M. ( 1985) Clinical pharmacokinetics of the salicylates. Clin Pharmacokinet10: 164-177.
108.
Nicholson, N.S., Panzer-Knodle, S.G., Haas, N.F., Taite, B.B., Szalony, J.A., Page, J.D. et al. (1998) Assessment of platelet function assays. Am Heart J135(5 Part 2 Suppl): S170-S178.
109.
Niitsu, Y., Jakubowski, J.A., Sugidachi, A. and Asai, F. ( 2005) Pharmacology of CS-747 (Prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity . Semin Thromb Hemost31: 184-194.
110.
Ogihara, Y., Muramatsu, S., Kaneda, Y., Iijima, T. and Shibutani, T. ( 2005) Pharmacological profile of DZ-697b, a novel anti-platelet agent-selective inhibitor of vWF- and collagen induced platelet aggregation . Blood106: 1875.
111.
Patrono, C., Ciabattoni, G., Patrignani, P., Pugliese, F., Filabozzi, P., Catella, F. et al. (1985) Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation72: 1177-1184.
112.
Patrono, C., Coller, B., FitzGerald, G.A., Hirsh, J. and Roth, G. ( 2004) Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest126(3 Suppl): 234S-264S.
113.
Patti, G., Colonna, G., Pasceri, V., Pepe, L.L., Montinaro, A. and Di Sciascio, G. ( 2005) Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation111: 2099-2106.
114.
Peto, R., Gray, R., Collins, R., Wheatley, K., Hennekens, C., Jamrozik, K. et al. (1988) Randomised trial of prophylactic daily aspirin inBritish male doctors. Br Med J (Clin Res Ed)296: 313-316.
115.
Pfisterer, M., Brunner-La Rocca, H.P., Buser, P.T., Rickenbacher, P., Hunziker, P., Mueller, C. et al. (2006) Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol48: 2584-2591.
116.
Physicians’ Health Study (1989) Physicians’ Health Study: aspirin and primary prevention of coronary heart disease. N Engl J Med321: 1825-1828.
117.
Price, M.J., Berger, P.B., Angiolillo, D.J., Teirstein, P.J., Tanquay, J.F., Kandzari, D.E. et al. (2009) Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J157: 818-824.
118.
Quick, A.J. ( 1966) Salicylates and bleeding: the aspirin tolerance test. Am J Med Sci252: 265-269.
119.
Quinn, M.J. and Topol, E.J. ( 2001) Common variations in platelet glycoproteins: pharmacogenomic implications. Pharmacogenomics2: 341-352.
120.
Ridker, P.M., Cook, N.R., Lee, I.M., Gordon, D., Gaziano, J.M., Manson, J.E. et al. (2005) A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med352: 1293-1304.
121.
Ross, R. ( 1999) Atherosclerosis-an inflammatory disease. N Engl J Med340: 115-126.
122.
Ruggeri, Z.M. ( 2002) Platelets in atherothrombosis. Nature Med8: 1227-1234.
123.
Sabatine, M.S., Cannon, C.P., Gibson, C.M., Lopez-Sendon, J.L., Montalescot, G., Theroux, P. et al. (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med352: 1179-1189.
124.
Samara, W.M. and Gurbel, P.A. ( 2003) The role of platelet receptors and adhesion molecules in coronary artery disease. Coron Artery Dis14: 65-79.
125.
Savage, B., Almus-Jacobs, F. and Ruggeri, Z.M. ( 1998) Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell94: 657-666.
126.
Savage, M.P., Goldberg, S., Bove, A.A., Deutsch, E., Vetrovec, G., Macdonald, R.G. et al. (1995) Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II). Circulation92: 3194-3200.
127.
Savi, P., Nurden, P., Nurden, A.T., Levy-Toledano, S. and Herbert, J.M. ( 1998) Clopidogrel: a review of its mechanism of action. Platelets9: 251-255.
128.
Saw, J., Steinhubl, S.R., Berger, P.B., Kereiakes, D.J., Serebruany, V.L., Brennan, D. et al. (2003) Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation108: 921-924.
129.
Schonbeck, U., Sukhova, G.K., Graber, P., Coulter, S. and Libby, P. ( 1999) Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol155: 1281-1291.
130.
Schror, K. ( 2002) The pharmacology of cilostazol. Diabetes Obes Metab4(Suppl 2(2)): S14-S19.
131.
Serebruany, V.L., Malinin, A.I., Atar, D. and Hanley, D.F. ( 2007) Consistent platelet inhibition during long-term maintenance-dose clopidogrel therapy among 359 compliant outpatients with documented vascular disease. Am Heart J153: 371-377.
132.
Serebruany, V.L., Malinin, A.I., Jerome, S.D., Lowry, D.R., Morgan, A.W., Sane, D.C. et al. (2003) Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. Am Heart J146: 713-720.
133.
Serebruany, V.L., Midei, M.G., Malinin, A.I., Oshrine, B.R., Lowry, D.R., Sane, D.C. et al. (2004) Absence of interaction between atorvastatin or other statins and clopidogrel: results from the Interaction Study. Arch Intern Med164: 2051-2057.
134.
Serebruany, V.L., Steinhubl, S.R., Berger, P.B., Malinin, A.I., Bhatt, D.L. and Topol, E.J. ( 2005) Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol45: 246-251.
135.
Shattil, S.J. ( 1995) Function and regulation of the beta 3 integrins in hemostasis and vascular biology. Thromb Haemost74: 149-155.
136.
Shibutani, T., Iijima, T., Kaneda, Y., Muramatsu, S. and Ogihara, Y. ( 2005) Anti-thrombotic action of DZ-697b, a novel Anti-platelet agent, on photochemically induced thrombosis with lower bleeding risk in guinea pigs. Blood106: 1870.
137.
Sibbing, D., Braun, S., Morath, T., Mehilli, J., Vogt, W., Schomig, A. et al. (2009) Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol53: 849-856.
138.
Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Meneveau, N. et al. (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med360: 363-375.
139.
Simoons, M.L. ( 2001) Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet357: 1915-1924.
140.
Smith Jr, S.C., Feldman, T.E., Hirshfeld Jr, J.W., Jacobs, A.K., Kern, M.J., King S.B., III et al. (2006) ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention) . Circulation113: e166-e286.
141.
Smith, S.M., Judge, H.M., Peters, G. and Storey, R.F. ( 2004) Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention. Platelets15: 465-474.
142.
Steinhubl, S.R., Berger, P.B., Mann J.T., III, Fry, E.T., DeLago, A., Wilmer, C. et al. (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA288: 2411-2420.
143.
Steinhubl, S.R., Ellis, S.G., Wolski, K., Lincoff, A.M. and Topol, E.J. ( 2001) Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation103: 1403-1409.
144.
Stone, G.W., Grines, C.L., Cox, D.A., Garcia, E., Tcheng, J.E., Griffin, J.J. et al. (2002) Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med346: 957-966.
145.
Stone, G.W., Mclaurin, B.T., Cox, D.A., Bertrand, M.E., Lincoff, A.M., Moses, J.W. et al. (2006) Bivalirudin for patients with acute coronary syndromes. N Engl J Med355: 2203-2216.
146.
Stone, G.W., Witzenbichler, B., Guagliumi, G., Peruga, J.Z., Brodie, B.R., Dudek, D. et al. (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med358: 2218-2230.
147.
Storey, R.F. ( 2001) The P2Y12 receptor as a therapeutic target in cardiovascular disease. Platelets12: 197-209.
148.
Storey, R.F. ( 2006) Biology and pharmacology of the platelet P2Y12 receptor . Curr Pharm Des12: 1255-1259.
149.
Storey, R.F., Husted, S., Harrington, R.A., Heptinstall, S., Wilcox, R.G., Peters, G. et al. (2007) Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol50: 1852-1856.
150.
Storey, R.F., Sanderson, H.M., White, A.E., May, J.A., Cameron, K.E. and Heptinstall, S. ( 2000) The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity . Br J Haematol110: 925-934.
151.
Sugidachi, A., Asai, F., Ogawa, T., Inoue, T. and Koike, H. ( 2000) The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol129: 1439-1446.
152.
Tantry, U.S., Bliden, K.P. and Gurbel, P.A. ( 2005) Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol46: 1705-1709.
153.
Taubert, D., Kastrati, A., Harlfinger, S., Gorchakova, O., Lazar, A., Von Beckerath, N. et al. (2004) Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost92: 311-316.
154.
The CAPTURE Investigators (1997) Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. Lancet349: 1429-1435.
155.
The EPIC Investigators (1994) Use of a monoclonal antibody directed against the platelet glycoprotein IIb/ IIIa receptor in high risk angioplasty. N Engl J Med330: 956-961.
156.
The EPILOG Investigators (1997) Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med336: 1689-1696.
157.
The EPISTENT Investigators (1998) Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of platelet IIb/IIa inhibitor for stenting. Lancet352: 87-92.
158.
The PARAGON Investigators (1998) International, randomized controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Platelet glycoprotein IIb/IIIa antagonism for the reduction of acute coronary syndrome events in a global organization network. Circulation97: 2386-2395.
159.
The Persantine-aspirin Reinfarction Study (PARIS) Research Group (1980) The Persantine-aspirin reinfarction study. Circulation62: V85-88.
160.
The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators (1998) A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med338: 1498-1505.
161.
The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators (1998) Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. N Engl J Med338: 1488-1497.
162.
The PURSUIT Trial Investigators (1998) Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med339: 436-443.
163.
The RISC Group (1990) Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet336: 827-830.
164.
Topol, E.J. ( 2001) Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the Gusto V randomised trial. Lancet357: 1905-1914.
165.
Van Giezen, J.J. and Humphries, R.G. ( 2005) pre-clinical and clinical studies with selective reversible direct P2y12 antagonists. Semin Thromb Hemost31: 195-204.
166.
Vivekananthan, D.P., Bhatt, D.L., Chew, D.P., Zidar, F.J., Chan, A.W., Moliterno, D.J. et al. (2004) Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol94: 358-360.
167.
von Beckerath, N., Taubert, D., Pogatsa-Murray, G., Schomig, E., Kastrati, A. and Schomig, A. ( 2005) Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation112: 2946-2950.
168.
Vorchheimer, D.A. and Becker, R. ( 2006) Platelets in atherothrombosis. Mayo Clin Proc81: 59-68.
169.
Wagner, D.D. and Burger, P.C. ( 2003) Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol23: 2131-2137.
170.
Wallentin, L., Becker, R.C., Budaj, A., Cannon, C.P., Emanuelsson, H., Held, C. et al. for the PLATO Investigators ( 2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med361: 1045-1057.
171.
Wang, T.H., Bhatt, D.L. and Topol, E.J. ( 2006) Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J27: 647-654.
172.
Weber, A.A., Zimmermann, K.C., Meyer-Kirchrath, J. and Schror, K. ( 1999) Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet353: 900.
173.
Wiviott, S.D., Antman, E.M., Winters, K.J., Weerakkody, G., Murphy, S.A., Behounek, B.D. et al. (2005) Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 Trial. Circulation111: 3366-3373.
174.
Wiviott, S.D., Braunwald, E., Mccabe, C.H., Montalescot, G., Ruzyllo, W., Gottlieb, S. et al. (2007a) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med357: 2001-2015.
175.
Wiviott, S.D., Trenk, D., Frelinger, A.L., O’donoghue, M., Neumann, F.J., Michelson, A.D. et al. (2007b) Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 Trial. Circulation116: 2923-2932.
176.
Wu, C.C. and Teng, C.M. ( 2006) Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation. Eur J Pharmacol546: 142-147.
177.
Wurtz, M., Grove, E.L., Kristensen, S.D. and Hvas, A.M.(2009) The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart96: 368-371.
178.
Yusuf, S., Zhao, F., Mehta, S.R., Chrolavicius, S., Tognoni, G. and Fox, K.K.Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med345: 494-502.
